Literature DB >> 9484402

Lhermitte's sign following chemotherapy with docetaxel.

M J van den Bent1, P H Hilkens, P A Sillevis Smitt, V J van Raaij-van den Aarssen, M Bontenbal, J Verweij.   

Abstract

Specific causes for Lhermitte's sign (LS) in cancer patients are spinal cord compression, radiation therapy to the spinal cord, and cisplatin chemotherapy. We observed a transient LS in five of 87 patients treated with more than two cycles of 100 mg/m2 docetaxel (Taxotere). LS developed either concurrently or after the onset of docetaxel-induced sensory neuropathy, and disappeared after the discontinuation or dose reduction of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484402     DOI: 10.1212/wnl.50.2.563

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.

Authors:  M I Koukourakis; A Giatromanolaki; S Kakolyris; M Froudarakis; V Georgoulias; G Retalis; N Bahlitzanakis
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 2.  A review on radiogenic Lhermitte's sign.

Authors:  Olga Esik; Tibor Csere; Klára Stefanits; Zsolt Lengyel; Géza Sáfrány; Katalin Vönöczky; Erzsébet Lengyel; Csaba Nemeskéri; Imre Repa; Lajos Trón
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

3.  PET identifies transitional metabolic change in the spinal cord following a subthreshold dose of irradiation.

Authors:  Olga Esik; Miklós Emri; Szabolcs Szakáll; Hans Herzog; Géza Sáfrány; Erzsébet Lengyel; András Boér; Gabriella Liszkay; Lajos Trón; Zsolt Lengyel; Imre Repa
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

4.  Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma.

Authors:  Bassem Youssef; JoAnn Shank; Jay P Reddy; Chelsea C Pinnix; George Farha; Mani Akhtari; Pamela K Allen; Michelle A Fanale; John A Garcia; Patricia H Horace; Sarah Milgrom; Grace Li Smith; Yago Nieto; Isadora Arzu; He Wang; Nathan Fowler; Maria Alma Rodriguez; Bouthaina Dabaja
Journal:  Radiat Oncol       Date:  2015-09-25       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.